BioMarin Pharmaceutical Inc. (BMRN) SVP Sells $312,927.50 in Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) SVP Brian Mueller sold 3,145 shares of the firm’s stock in a transaction that occurred on Friday, June 22nd. The shares were sold at an average price of $99.50, for a total value of $312,927.50. Following the completion of the transaction, the senior vice president now owns 12,375 shares in the company, valued at approximately $1,231,312.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Brian Mueller also recently made the following trade(s):

  • On Friday, June 15th, Brian Mueller sold 2,021 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $94.50, for a total value of $190,984.50.
  • On Thursday, May 10th, Brian Mueller sold 2,450 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $89.50, for a total value of $219,275.00.

Shares of BioMarin Pharmaceutical opened at $91.15 on Friday, according to MarketBeat. BioMarin Pharmaceutical Inc. has a twelve month low of $75.81 and a twelve month high of $99.76. The company has a quick ratio of 2.29, a current ratio of 2.90 and a debt-to-equity ratio of 0.29. The firm has a market capitalization of $16.21 billion, a PE ratio of -136.04 and a beta of 1.71.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Wednesday, April 25th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.08). BioMarin Pharmaceutical had a negative net margin of 10.48% and a negative return on equity of 3.01%. The firm had revenue of $373.45 million during the quarter, compared to analyst estimates of $348.73 million. During the same period in the previous year, the firm posted $0.20 earnings per share. The company’s quarterly revenue was up 22.9% compared to the same quarter last year. research analysts anticipate that BioMarin Pharmaceutical Inc. will post -0.12 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Ladenburg Thalmann Financial Services Inc. grew its stake in shares of BioMarin Pharmaceutical by 22.9% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,224 shares of the biotechnology company’s stock valued at $287,000 after buying an additional 600 shares in the last quarter. Glenmede Trust Co. NA grew its stake in shares of BioMarin Pharmaceutical by 3.7% in the fourth quarter. Glenmede Trust Co. NA now owns 17,520 shares of the biotechnology company’s stock valued at $1,562,000 after buying an additional 622 shares in the last quarter. First Light Asset Management LLC grew its stake in shares of BioMarin Pharmaceutical by 2.0% in the first quarter. First Light Asset Management LLC now owns 31,850 shares of the biotechnology company’s stock valued at $2,582,000 after buying an additional 637 shares in the last quarter. ETRADE Capital Management LLC grew its stake in BioMarin Pharmaceutical by 9.5% during the 1st quarter. ETRADE Capital Management LLC now owns 7,545 shares of the biotechnology company’s stock worth $612,000 after purchasing an additional 653 shares in the last quarter. Finally, Commerce Bank grew its stake in BioMarin Pharmaceutical by 29.5% during the 4th quarter. Commerce Bank now owns 2,907 shares of the biotechnology company’s stock worth $259,000 after purchasing an additional 662 shares in the last quarter.

Several research firms have recently weighed in on BMRN. Zacks Investment Research downgraded BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Tuesday. JPMorgan Chase & Co. restated a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Wednesday, June 20th. BidaskClub downgraded BioMarin Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, June 8th. Citigroup raised their target price on BioMarin Pharmaceutical to $108.00 and gave the company a “buy” rating in a research report on Tuesday, May 29th. Finally, ValuEngine upgraded BioMarin Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Monday, May 28th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. BioMarin Pharmaceutical presently has a consensus rating of “Buy” and an average target price of $112.50.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply